AAT Resistance-related AC007405.2 and AL354989.1 As Novel Diagnostic and Prognostic Markers in Prostate Cancer

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2024 Apr 21

PMID 38643469

Authors

Yuanzhong Deng

Chunlin Zhang

Haitao Yu

Guo Chen

Xiang Peng

Yang Li

Zhenwei Feng

Wei Shi

Xuesong Bai

Xin Gou

Nian Liu

Affiliations

Soon will be listed here.

Abstract

Objective: Prostate cancer (PCa) is the second disease threatening men's health, and anti-androgen therapy (AAT) is a primary approach for treating this condition. Increasing evidence suggests that long non-coding RNAs (lncRNAs) play crucial roles in the development of PCa and the process of AAT resistance. The objective of this study is to utilize bioinformatics methods to excavate lncRNAs association with AAT resistance and investigate their biological functions.

Methods: AAT resistance-related risk score model (ARR-RSM) was established by multivariate Cox analysis. Paired clinical tissue samples of 36 PCa patients and 42 blood samples from patients with PSA over 4 ng/ml were collected to verify the ARR-RSM. , RT-qPCR, CCK-8 and clone formation assays were displayed to verify the expression and function of AL354989.1 and AC007405.2.

Results: Pearson correlation analysis identified 996 lncRNAs were associated with AAT resistance (ARR-LncRs). ARR-RSM was established using multivariate Cox regression analysis, and PCa patients were divided into high-risk and low-risk groups. High-risk patients showed increased expression of AL354989.1 and AC007405.2 had poorer prognoses. The high-risk score correlated with advanced T-stage and -stage. The AUC of ARR-RSM outperformed tPSA in diagnosing PCa. Silencing of AC007405.2 and AL354989.1 inhibited PCa cells proliferation and AAT resistance.

Conclusions: In this study, we have discovered the clinical significance of AC007405.2 and AL354989.1 in predicting the prognosis and diagnosing PCa patients. Furthermore, we have confirmed their correlation with various clinical features. These findings provide potential targets for PCa treatment and a novel diagnostic and predictive indicator for precise PCa diagnosis.

References

Dess R, Sun Y, Jackson W, Jairath N, Kishan A, Wallington D . Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020; 6(5):735-743. PMC: 7189892. DOI: 10.1001/jamaoncol.2020.0109. View

Zhang Y, Huang Y, Wang D, Yang B, Yan H, Lin L . LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network. Theranostics. 2020; 10(23):10823-10837. PMC: 7482804. DOI: 10.7150/thno.47830. View

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

Mirzaei S, Paskeh M, Okina E, Gholami M, Hushmandi K, Hashemi M . Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res. 2022; 41(1):214. PMC: 9248128. DOI: 10.1186/s13046-022-02406-1. View

van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M . Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022; 19(9):562-572. DOI: 10.1038/s41585-022-00638-6. View

Chan J, Zaidi S, Love J, Zhao J, Setty M, Wadosky K . Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science. 2022; 377(6611):1180-1191. PMC: 9653178. DOI: 10.1126/science.abn0478. View

Herman A, Tsitsipatis D, Gorospe M . Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022; 82(12):2252-2266. PMC: 9219586. DOI: 10.1016/j.molcel.2022.05.027. View

Ilic D, Djulbegovic M, Jung J, Hwang E, Zhou Q, Cleves A . Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018; 362:k3519. PMC: 6283370. DOI: 10.1136/bmj.k3519. View

Mottet N, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020; 79(2):243-262. DOI: 10.1016/j.eururo.2020.09.042. View

10.

Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang B . LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex. Nucleic Acids Res. 2019; 47(8):4211-4225. PMC: 6486551. DOI: 10.1093/nar/gkz108. View

11.

Zhang Y, Guo S, Wang S, Li X, Hou D, Li H . LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7A11 signaling. Ecotoxicol Environ Saf. 2021; 220:112376. DOI: 10.1016/j.ecoenv.2021.112376. View

12.

Bach C, Pisipati S, Daneshwar D, Wright M, Rowe E, Gillatt D . The status of surgery in the management of high-risk prostate cancer. Nat Rev Urol. 2014; 11(6):342-51. DOI: 10.1038/nrurol.2014.100. View

13.

Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K . Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. Eur Urol. 2022; 81(5):446-455. PMC: 9018600. DOI: 10.1016/j.eururo.2021.12.039. View

14.

Chen B, Xu K, Zhang Y, Xu P, Li C, Liu J . LncRNA ERVH48-1 Contributes to the Drug Resistance of Prostate Cancer and Proliferation through Sponging of miR-4784 to the Activation of the Wnt/β-Catenin Pathway. Cancers (Basel). 2023; 15(6). PMC: 10046998. DOI: 10.3390/cancers15061902. View

15.

Tilki D, Chen M, Wu J, Huland H, Graefen M, DAmico A . Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death. J Clin Oncol. 2022; 40(20):2186-2192. PMC: 9273369. DOI: 10.1200/JCO.21.02800. View

16.

Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y . lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell. 2018; 33(4):706-720.e9. PMC: 6143179. DOI: 10.1016/j.ccell.2018.03.006. View

17.

Kang J, La Manna F, Bonollo F, Sampson N, Alberts I, Mingels C . Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022; 530:156-169. DOI: 10.1016/j.canlet.2022.01.015. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Lenfant L, Barret E, Roupret M, Rozet F, Ploussard G, Mozer P . Transperineal Prostate Biopsy Is the New Black: What Are the Next Targets?. Eur Urol. 2022; 82(1):3-5. DOI: 10.1016/j.eururo.2022.01.046. View

20.

Wang B, Zhang S, Meng J, Min L, Luo J, Zhu Z . Evaporation-Induced rGO Coatings for Highly Sensitive and Non-Invasive Diagnosis of Prostate Cancer in the PSA Gray Zone. Adv Mater. 2021; 33(40):e2103999. DOI: 10.1002/adma.202103999. View